Your browser doesn't support javascript.
loading
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Marouf, A; Molinari, N; Sibon, D; Cottereau, A S; Kanoun, S; Antoine, C; Debureaux, P E; Cavalieri, D; Fornecker, L M; Casasnovas, R O; Herbaux, C; Amorim, S; Rossi, C; Bouscary, D; Brice, P; Ghesquieres, H; Tamburini, J; Deau, B.
Affiliation
  • Marouf A; Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France.
  • Molinari N; Service Hématologie, AP-HP, Hôpital Cochin, Paris, France.
  • Sibon D; Groupe Hospitalier privé Ambroise Paré-Hartmann, Département Recherche Innovation, Neuilly-Sur-Seine, France.
  • Cottereau AS; IDESP, INSERM, PreMEdical INRIA, Univ Montpellier, CHU Montpellier, Montpellier, France.
  • Kanoun S; Paris Est University, Créteil, France.
  • Antoine C; Service Hémopathies Lymphoïdes, AP-HP, Hôpital Henri Mondor, Créteil, France.
  • Debureaux PE; Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France.
  • Cavalieri D; Service de Médecine Nucléaire, AP-HP, Hôpital Cochin, Paris, France.
  • Fornecker LM; Centre de Recherche Clinique de Toulouse, Team 9, Toulouse, France.
  • Casasnovas RO; Lymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging, Hôpital Henri Mondor, Créteil, France.
  • Herbaux C; Saint Louis Research Institute, INSERM U1160, Paris, France.
  • Amorim S; Service Hématologie, CHRU Lille, Lille, France.
  • Rossi C; Université de Strasbourg, INSERM S-1113, Strasbourg, France.
  • Bouscary D; Service Hématologie, Cancéropôle Est, Strasbourg, France.
  • Brice P; UFR des Sciences de Santé, INSERM UMR 1231 CHU Dijon, Dijon, France.
  • Ghesquieres H; Service Hématologie, CHU Dijon, Dijon, France.
  • Tamburini J; Service Hématologie, CHU Montpellier, Montpellier, France.
  • Deau B; Service Hématologie, Hôpital Saint-Louis, Paris, France.
Br J Haematol ; 202(2): 379-383, 2023 07.
Article in En | MEDLINE | ID: mdl-37192755
ABSTRACT
Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high-risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV-naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV-exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Immunoconjugates / Hematopoietic Stem Cell Transplantation Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Br J Haematol Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Immunoconjugates / Hematopoietic Stem Cell Transplantation Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Br J Haematol Year: 2023 Document type: Article Affiliation country: